Hydroxyurea is a medication that has been used for many years to treat myeloproliferative neoplasms (MPNs). It is particularly effective in treating polycythemia vera (PV) and essential thrombocythemia (ET), where it reduces the number of abnormal blood cells and decreases the risk of blood clots and other complications associated with these conditions.
Hydroxyurea works by inhibiting DNA synthesis in the bone marrow, which reduces the number of abnormal blood cells produced. It is generally well-tolerated, and its effectiveness can be monitored through regular blood tests. However, some patients may experience side effects such as anemia, fatigue, and skin rash.
Despite these potential side effects, hydroxyurea remains an important treatment option for Myeloproliferative Neoplasms, and its use has greatly improved the quality of life for many patients with these conditions.
Read more: https://cmiaspireblog.blogspot.com/2023/04/understanding-myeloproliferative.html
Sign in to leave a comment.